Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Apr 15;231(4):e638-e649.
doi: 10.1093/infdis/jiaf032.

Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

Penelope Gray  1 , Jiangrong Wang  1 , Sara Nordqvist Kleppe  1 , K Miriam Elfström  1   2 , Joakim Dillner  1
Affiliations

Population-Based Age-Period-Cohort Analysis of Declining Human Papillomavirus Prevalence

Penelope Gray et al. J Infect Dis. .

Abstract

Background: Most countries in the world have launched human papillomavirus (HPV) vaccination programs, and declining HPV prevalences are reported. We aimed to disentangle the influences of calendar time, birth cohort, and age by analyzing HPV prevalences in the population-based cervical screening program using age-period-cohort modeling.

Methods: All 813 882 primary HPV-based cervical screening tests from women aged 23-64 years between 2014 and 2023 in the capital region of Sweden were identified in the Swedish National Cervical Screening Registry. The odds ratio (OR) of HPV-16/18 infection was estimated comparing birth cohorts to the unvaccinated 1984-born using an age-period-cohort model. The impact of changing HPV prevalences on the number needed to screen (NNS) to detect and prevent 1 cervical cancer case was calculated.

Results: HPV vaccination coverage was 82%-83% among women born in 1999-2000. Before 2019, the HPV-16/18 prevalence was highest among the youngest women. During 2020-2023 the prevalence consistently decreased among the birth cohorts offered organized school-based vaccination. There was a 98% decline in HPV-16 prevalence (OR, 0.02 [95% confidence interval {CI}, .01-.04]) and a 99% decline in HPV-18 prevalence (OR, 0.01 [95% CI, .00-.04]) among the 2000-born compared to the 1984-born. The declining HPV-16/18 prevalences resulted in major increases in the NNS to detect and to prevent 1 case of cervical cancer.

Conclusions: The declines of HPV-16/18 were considerably larger than the vaccination coverage, suggesting herd immunity. The changing epidemiology of HPV types impacts screening needs, necessitating updated screening programs.

Keywords: HPV; HPV elimination; HPV prevalence; HPV vaccination; cervical screening; herd protection.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. J. W. and S. N. K. have participated in other studies (unrelated to this study) funded by MSD regarding HPV vaccination evaluation in Sweden. All other authors report no potential conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Flowchart of the repeated cross-sectional study of women attending human papillomavirus–based cervical screening from 2014 through 2023. Abbreviations: HPV, human papillomavirus; NKCx, Swedish National Cervical Screening Registry.
Figure 2.
Figure 2.
Lexis diagrams of the human papillomavirus (HPV) vaccination coverage among females residing in Sweden from 2005 to 2023 (A), and HPV-16 prevalence (B) and HPV-18 prevalence (C) among women attending cervical screening in the Stockholm region.
Figure 3.
Figure 3.
Estimated odds ratios (95% confidence intervals [CIs]) comparing the odds of human papillomavirus (HPV) type 16 and 18 positivity among birth cohorts relative to the 1984 birth cohort (the reference cohort where HPV vaccination coverage was negligible), as estimated via the age-period-cohort model plotted against the HPV-unvaccinated percentage (1 minus the HPV vaccination coverage) of women in Sweden. The shaded area around the line represents the 95% CIs.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer (IARC) . Biological agents. IARC monographs on the evaluation of carcinogenic risks to humans. Volume 100B. Lyon, France: IARC, 2012.
    1. Ault KA. Epidemiology and natural history of human papillomavirus infections in the female genital tract. Infect Dis Obstet Gynecol 2006; 2006:40470. - PMC - PubMed
    1. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat Rev Microbiol 2012; 10:681–92. - PMC - PubMed
    1. Malagón T, Drolet M, Boily MC, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012; 12:781–9. - PubMed
    1. Baussano I, Lazzarato F, Ronco G, Franceschi S. Impacts of human papillomavirus vaccination for different populations: a modeling study. Int J Cancer 2018; 143:1086–92. - PMC - PubMed

MeSH terms

Substances